Panel Discussion: A Brief History – Why Haven’t Advancements in Targeted- & Immunotherapies Had More Impact on GI Cancers?

Time: 8:30 am
day: Day One


  • With many promising candidates in targeted and immunotherapy simply not meeting expectations, where should we be looking?
  • Understanding and translation of the pathologies of various GI cancers: MSS vs MSI CRC, HCC, PDAC & more
  • Where is the field moving? Which tumors to focus certain therapeutics on?
  • How will early detection, precision oncology & patient groups mould this landscape?